Paul Nunzio DeSantis, Pharm.D
Contributor since: 2014
Company: Alpha BioPharma Advisers
Articles
Biotech Sector: Reformed Views On Our Short Ideas After Sell-Off
Clovis: Execution Risk, Loss Of Credibility, & Regulatory Missteps Constrain Valuation
ASCO 2015: Karyopharm Therapeutics Solid Tumor Optionality Undervalued (Summary Version)
Vertex Pharmaceuticals: Short-Term Dominance In Cystic Fibrosis Is Questionable Longer Term
Tekmira/Oncore Merger Represents Substantial Upside
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Insuline: Significant Upside, Alternative Diabetes Play With A Population Based Cost-Reduction Platform In Diabetes
Achillion: Positioned To Deliver The Last Clinical Stage Nuc To The Highest Bidder
Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gilead Most Likely Suitor
pSivida Corp.: Imminent New Drug Approval, Steady News Flow, And Tethadur Partnership Raising Price Target To $10/Share
Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences Later This Year
Gilead Sciences Should Report $4B In Sovaldi Sales In Q2'14
Gilead's Pipeline Requires MacroGenics' ImmunoOncology Platform (M&A)
Consider Shire Pharmaceuticals Now; 20%+ Upside Left In Takeover Bid By AbbVie
Merck's Acquisition Of Idenix Pharmaceuticals Is An Admission Of Inferiority To Sovaldi Regimens
OncoGenex: Phase III Trial In First Line Metastatic Prostate Cancer Fails, Now What?
Gilead: X-Marks The Spot For Sovaldi Sales
Intercept Pharmaceuticals (Part IIa) - Quick Takeaways On OCA From EASL Abstracts And Presentations
Intercept Pharmaceuticals (Part II): The Short Story Is Over, Time For The Long Story
Chelsea Therapeutics: Caution Warranted
A Picture Is Worth A Thousand Words: Implications From Sovaldi Treatment Trends
pSivida: Positive Roche And Regeneron Conference Calls Confirm Tehadur's Potential
Pioneer Natural Resources: A Deep Dive Suggests Possible M&A Upside
Gilead: A Solid 2014 Outlook Still Looks Conservative; Strong Buy
Gilead: Patient Checkup (Earnings Preview)
Gilead: The Rising Tide Is Coming
The Short Story Of Intercept Pharmaceuticals (Part I): A Conference Call With Expert Physicians
The Gilead Rebuttal